scPharmaceuticals, based in Burlington, Massachusetts, focuses on developing subcutaneous delivery products like FUROSCIX for outpatient care. The company, founded in 2017 and employing 135 staff, aims to enhance patient care and reduce healthcare costs.
scPharmaceuticals (SCPH) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, scPharmaceuticals's actual EPS was -$0.35, beating the estimate of -$0.39 per share, resulting in a 9.30% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
